#3706 EFFECT OF CHOLECALCIFEROL INTAKE ON NOVEL INFLAMMATORY INDICATORS IN HEMODIALYSIS PATIENTS

Abstract

Abstract Background and Aims Hemodialysis patients (HD) are in a chronic state of systemic inflammation, with vast majority of these patients are vitamin D deficient. Vitamin D appears to be a strong controller of inflammation. It's well known that C-reactive protein (CRP) is considered the gold of inflammatory markers. Recently, neutrophil- to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been shown to be inexpensive, readily available indicators of systemic inflammation. This study is to demonstrate the pleotropic effects, the efficacy and the safety of two dosing regimens of cholecalciferol; (weekly regimen vs monthly regimen) on novel inflammatory indicators in HD population. Method A prospective, randomized trial was carried out to evaluate the effect of weekly versus, monthly oral cholecalciferol, on vitamin D (25(OH)D) levels, on inflammatory markers and secondary hyperparathyroidism in HD patients. Fifty eligible HD patients were randomly assigned to either Group A (Once weekly oral 50.000IU Cholecalciferol) or Group B (One monthly, oral 200.000IU Cholecalciferol), for 3 months’ period. Serum levels of high sensitive CRP (hsCRP), NLR, PLR, were all assessed at baseline and at the end of the study. Results Cholecalciferol significantly increased serum levels of 25(OH)D in both groups. A significant decrease in serum hsCRP levels (p <0.001) and NLR was noted only in Group A. No significant difference in calcium or phosphorus levels was noticed. No side effects or adverse events were reported. Conclusion Weekly (50.000 IU) oral cholecalciferol appears to have a beneficial action on replenishing 25(OH)D levels in HD patients, with an ameliorative action on inflammatory status as well. NLR seems to be an effective, non-expensive inflammatory indicator in HD.